Diagnosis of Growth Hormone Deficiency
The hallmarks of classic Ghd include extreme proportional short stature with a very slow growth velocity and a delayed bone age. children with children treated with rhGh between 1985 to 1994 showed that 44 % had idiopathic Ghd, while 13.8 % had organic Ghd. 6 of those with organic Ghd a small subgroup have Ghd as a part of a larger complex of pituitary deficiencies. Most common is septo-optic dysplasia, which may include varying degrees of hypopituitarism. also in this group are rare inherited syndromes of hypopituitarism caused by mutations in the transcription factors prophet of Pit-1 (Pou1F1) (homologous to the mouse gene Pit-1) and PRoP1, so named because it was recognized to be related to Pou1F1. 7 another rare cause of organic Ghd is caused by a problem with a more recent approach has been to adjust the Gh dose based on iGF-i levels, rather than relying on weight-based dosing. a study using this paradigm has shown that such an approach may result in increased growth velocities; however, the doses in some subjects were so high as to be prohibitively expensive. 24 This method of dosing does provide for safety, however, since it involves frequent monitoring of iGF-i levels.
Compliance Concerns
a common problem with Gh therapy has been compliance. ideally, Gh should be taken daily, but since there is little loss of growth from skipping a single dose, patients may be tempted to skip doses. one approach to this problem has been renewed interest in long-acting Gh preparations.
Such a preparation, which was given once or twice monthly, was in use about a decade ago, 25 but for various reasons (some having to do with the logistics of manufacture), the preparation is no longer available. in addition, other problems with this preparation included inconvenience in the size of the injections (occasionally requiring dividing the dose into more than one injection) and the need for a larger needle in order to avoid clumping of the dose in the syringe as the injection was being given.
Similar preparations under development have attempted to address some of these earlier problems. it is intuitive that the ideal Gh preparation should result in physiologic Gh secretion, which would be multiple bursts of Gh each day, particularly during sleep, 26 however, it should be pointed out that daily Gh does not accomplish this. Subcutaneously injected daily Gh peaks at about 5 hours after injection and persists for about 24 hours. 27 The long-acting Gh preparation that was previously available resulted in a large initial peak of Gh, followed by a tail that lasted about 2 weeks. 25 careful examination of Gh response to this preparation demonstrated that the growth response was most correlated not with the peak Gh value or with the complete area under the curve, but with the length of the exposure to Gh, that is, with the area under the curve of the tail. Therefore, since the first goal of treatment is a good Gh response, the long-acting Gh preparation that produces the best effect on growth may not necessarily be the one that mimics the most physiologic secretion pattern. although there are no Fda-approved long-acting Gh preparations currently available, there are several that are in various stages of development. [28] [29] [30] [31] Most of the long-acting Gh preparations under study are designed to be injected weekly.
Growth Hormone Therapy During Puberty
another challenging aspect of Gh therapy is the care of the child who is in puberty. 32 Patients with Ghd are usually treated until they have reached an acceptable height, or until they experience epiphyseal fusion and are no longer able to respond to Gh with linear growth. The usual point for stopping Gh because of epiphyseal fusion is an annual growth velocity slower than 2.5 cm per year in a patient who is known to be compliant with the Gh injections. aromatase inhibitors block conversion of testosterone to estradiol, and cause an increase testosterone levels behind the block. it is because of the increased testosterone levels that there has been reluctance to study these preparations in girls. With aromatase inhibitors there is no stopping of male puberty (male puberty may actually accelerate because of the testosterone build up). The results of these studies are just becoming available; 39,40 it appears that treatment with an aromatase inhibitor significantly increases the height prediction in a pubertal male, and there do not appear to be any serious safety signals with its use.
Treatment with Insulin-like Growth Factor
Since its approval by the Fda in 2005, it has been possible to use iGF-i as a treatment for short stature. 41 in general its most appropriate application is in treating Gh-resistant conditions, such as GhiS or laron Syndrome.
however, there are some specific uses for this therapy in rare cases of severe familial Gh deficiency. First described in 1978 in a consanguineous family, 42 Ghd type ia was determined to be the result of absence of the Gh gene. 43 other similar patients have been described, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] and the extent of the Gh gene deletions vary among the reported cases.
children with type ia have the severest form of Ghd. 58 at birth they are short and somewhat obese with a small head circumference. Boys have micropenis. all infants have problems with hypoglycemia. These children grow very slowly, and usually more than 2 Sd below the mean in height.
They also have delay in motor development. They have a protruding forehead and a saddle nose, and sparse hair. These children test Gh deficient and also dNa analysis demonstrates a deletion in the Gh gene.
What is particularly characteristic of children with type i Ghd is that some of the patients produce antibodies against Gh when they are treated. These antibody titers may become quite high-high enough to attenuate their growth response to treatment. 45, 59 interestingly, there are patients with type i Ghd in whom these antibodies do not develop. 46 
Adult Growth Hormone Deficiency
it is now recognized that some Gh-deficient children will not make 
Safety of Growth Hormones
Gh adverse events have been carefully documented in reviews of Gh therapy. 65, 66 Most adverse events have been local injection site reactions, which rarely lead to discontinuation. headache, nausea, and fever have been generally self-limiting and are well tolerated. adverse events such as edema or carpal tunnel syndrome are seen more often in adults than children, and may be the result of fluid retention caused by Gh. 67 adverse events seen particularly in children have included transient idiopathic intracranial hypertension (iih, also known as pseudotumor cerebri), gynecomastia, and slipped capital femoral epiphysis. 68, 69 The iih usually resolves after discontinuation of Gh and re-starting at a low dose.
overall, Gh has been shown to be a safe hormone when used at recommended doses. 
